13.26
price up icon3.51%   0.45
after-market アフターアワーズ: 13.25 -0.010 -0.08%
loading
前日終値:
$12.81
開ける:
$13.11
24時間の取引高:
3.00M
Relative Volume:
0.65
時価総額:
$1.57B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-3.4652
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
+0.38%
1か月 パフォーマンス:
-1.19%
6か月 パフォーマンス:
-20.17%
1年 パフォーマンス:
+51.89%
1日の値動き範囲:
Value
$13.03
$13.67
1週間の範囲:
Value
$12.63
$13.67
52週間の値動き範囲:
Value
$5.90
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1114)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
13.26 1.51B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Mar 25, 2026

Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn

Mar 25, 2026
pulisher
Mar 24, 2026

Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review

Mar 24, 2026
pulisher
Mar 23, 2026

Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn

Mar 23, 2026
pulisher
Mar 22, 2026

Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Mar 22, 2026
pulisher
Mar 22, 2026

NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 22, 2026
pulisher
Mar 21, 2026

Intellia rises on Q4 earnings & revenue beat, focuses on pipeline - MSN

Mar 21, 2026
pulisher
Mar 21, 2026

Intellia jumps as FDA lifts clinical hold on Nex-Z for ATTR-CM - MSN

Mar 21, 2026
pulisher
Mar 20, 2026

How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - Stock Traders Daily

Mar 20, 2026
pulisher
Mar 18, 2026

Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill

Mar 18, 2026
pulisher
Mar 17, 2026

Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool

Mar 17, 2026
pulisher
Mar 16, 2026

Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat

Mar 16, 2026
pulisher
Mar 12, 2026

KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha

Mar 12, 2026
pulisher
Mar 12, 2026

Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Acti - GuruFocus

Mar 12, 2026
pulisher
Mar 10, 2026

Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing? - Sahm

Mar 10, 2026
pulisher
Mar 09, 2026

Intellia Therapeutics at Leerink Global Healthcare Conference: Gene Editing Prospects - Investing.com Canada

Mar 09, 2026
pulisher
Mar 09, 2026

Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha

Mar 09, 2026
pulisher
Mar 09, 2026

NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView

Mar 09, 2026
pulisher
Mar 09, 2026

(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 09, 2026
pulisher
Mar 08, 2026

Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI

Mar 08, 2026
pulisher
Mar 08, 2026

This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq

Mar 08, 2026
pulisher
Mar 08, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm

Mar 08, 2026
pulisher
Mar 07, 2026

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat

Mar 07, 2026
pulisher
Mar 07, 2026

Intellia Therapeutics Q4 2025 earnings preview - MSN

Mar 07, 2026
pulisher
Mar 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 06, 2026
pulisher
Mar 06, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Mar 06, 2026
pulisher
Mar 06, 2026

CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan

Mar 06, 2026
pulisher
Mar 05, 2026

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits

Mar 05, 2026
pulisher
Mar 05, 2026

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA) - The Globe and Mail

Mar 05, 2026
pulisher
Mar 05, 2026

Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st

Mar 05, 2026
pulisher
Mar 05, 2026

A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance

Mar 05, 2026
pulisher
Mar 05, 2026

Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Mar 05, 2026
pulisher
Mar 05, 2026

ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Mar 05, 2026
pulisher
Mar 04, 2026

Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq

Mar 04, 2026
pulisher
Mar 04, 2026

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive

Mar 04, 2026
pulisher
Mar 04, 2026

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Mar 04, 2026
pulisher
Mar 04, 2026

NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat

Mar 04, 2026
pulisher
Mar 04, 2026

Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka

Mar 04, 2026
pulisher
Mar 03, 2026

Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan

Mar 03, 2026
pulisher
Mar 03, 2026

Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat

Mar 03, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):